Attovia Therapeutics priced its upsized IPO on August 4 at the top of the range, selling 17 million shares at $17 to raise $289 million and implying a $731.5 million market capitalization based on shares outstanding. The early-stage biotech’s ATTOBODY platform targets immune-mediated conditions with lead candidate ATTO-1310 in Phase 1 and bispecific programs advancing toward 2027 trials, positioning it against established therapies such as Dupixent. Strong institutional demand, including Goldman Sachs backing and recent private rounds at a $379 million post-money valuation, supported pricing near the $700-800 million bin that currently leads Polymarket odds at 28.5%. With multiple adjacent ranges holding comparable probabilities, trader sentiment reflects uncertainty over final share count adjustments, lockup dynamics, and post-listing trading volume on the August 5 Nasdaq debut.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato700M$-800M$ 29%
600M$-700M$ 27%
900M$-1B$ 24%
800M-900M $ 19%
NUOVO
NUOVO
5 ago 2026
<600M $
9%
600M$-700M$
27%
700M$-800M$
29%
800M-900M $
19%
900M$-1B$
24%
Oltre 1 miliardo di dollari
14%
Nessuna IPO prima di ottobre 2026
9%
700M$-800M$ 29%
600M$-700M$ 27%
900M$-1B$ 24%
800M-900M $ 19%
NUOVO
NUOVO
5 ago 2026
<600M $
$3 Vol.
9%
600M$-700M$
$0 Vol.
27%
700M$-800M$
$14 Vol.
29%
800M-900M $
$0 Vol.
19%
900M$-1B$
$0 Vol.
24%
Oltre 1 miliardo di dollari
$244 Vol.
14%
Nessuna IPO prima di ottobre 2026
$10 Vol.
9%
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Attovia Therapeutics priced its upsized IPO on August 4 at the top of the range, selling 17 million shares at $17 to raise $289 million and implying a $731.5 million market capitalization based on shares outstanding. The early-stage biotech’s ATTOBODY platform targets immune-mediated conditions with lead candidate ATTO-1310 in Phase 1 and bispecific programs advancing toward 2027 trials, positioning it against established therapies such as Dupixent. Strong institutional demand, including Goldman Sachs backing and recent private rounds at a $379 million post-money valuation, supported pricing near the $700-800 million bin that currently leads Polymarket odds at 28.5%. With multiple adjacent ranges holding comparable probabilities, trader sentiment reflects uncertainty over final share count adjustments, lockup dynamics, and post-listing trading volume on the August 5 Nasdaq debut.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercato aperto: Aug 4, 2026, 9:51 PM ET
Volume
$271Data di fine
5 ago 2026Mercato aperto
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Attovia Therapeutics priced its upsized IPO on August 4 at the top of the range, selling 17 million shares at $17 to raise $289 million and implying a $731.5 million market capitalization based on shares outstanding. The early-stage biotech’s ATTOBODY platform targets immune-mediated conditions with lead candidate ATTO-1310 in Phase 1 and bispecific programs advancing toward 2027 trials, positioning it against established therapies such as Dupixent. Strong institutional demand, including Goldman Sachs backing and recent private rounds at a $379 million post-money valuation, supported pricing near the $700-800 million bin that currently leads Polymarket odds at 28.5%. With multiple adjacent ranges holding comparable probabilities, trader sentiment reflects uncertainty over final share count adjustments, lockup dynamics, and post-listing trading volume on the August 5 Nasdaq debut.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$271Data di fine
5 ago 2026Mercato aperto
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...Attovia Therapeutics priced its upsized IPO on August 4 at the top of the range, selling 17 million shares at $17 to raise $289 million and implying a $731.5 million market capitalization based on shares outstanding. The early-stage biotech’s ATTOBODY platform targets immune-mediated conditions with lead candidate ATTO-1310 in Phase 1 and bispecific programs advancing toward 2027 trials, positioning it against established therapies such as Dupixent. Strong institutional demand, including Goldman Sachs backing and recent private rounds at a $379 million post-money valuation, supported pricing near the $700-800 million bin that currently leads Polymarket odds at 28.5%. With multiple adjacent ranges holding comparable probabilities, trader sentiment reflects uncertainty over final share count adjustments, lockup dynamics, and post-listing trading volume on the August 5 Nasdaq debut.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti